Mice treated with antibody therapy (anti-GITR and anti-PD-1 Abs) or peritumoral DR-BMCs showed a modest delay in tumor growth with a median survival of 31 and 33 days, respectively, compared to untreated mice (median survival – 28 days). Here, TNFRSF18 is linked to neoplasm.